A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
In this research study, our main goal for the ipilimumab portion of the study is to determine
the highest dose of ipilimumab that can be given safely in several courses and to determine
what side effects are seen in patients with Acute Myeloid Leukemia (AML), Myelodysplastic
Syndromes (MDS), Myeloproliferative Neoplasms (MPN), Chronic Myelomonocytic Leukemia (CMML),
or Myelofibrosis (MF).